Written Question·Department of Health and Social Care·UIN 37488

Myasthenia Gravis: Medical Treatments

Tabled: 11 March 2025

Answered: 18 March 2025

Question

Sadik Al-Hassan

To ask the Secretary of State for Health and Social Care, what his planned timetable is for when patients with Myasthenia Gravis will have access to recently licenced products.

Answer

Karin Smyth

On 7 March 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the medicine rozanolixizumab, marketed as Rystiggo, to treat adults with generalised myasthenia gravis.The National Institute for Health and Care Excellence (NICE) ev...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 37488) →